Dr. Ansell on Strategies to Address Immune Evasion in Lymphoma

Stephen M. Ansell, MD, PhD
Published: Monday, Aug 06, 2018



Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

One of the most successful strategies to overcome immune evasion is to prevent T cell exhaustion. When T cells get activated and produce proteins such as PD-1, it puts them at risk for being suppressed if the ligand PD-L1 or PD-L2 signals through PD-1, Ansell explains. Other receptors such as TIM-3 and LAG-3 are important, Ansell adds, and those begin to increase as the T cell becomes exhausted. Strategies to keep the immune system engaged involve blocking these negative systems. Blocking PD-1 has already proved to be successful in lymphoma, but there are new trials blocking TIM-3 and LAG-3, Ansell says.

Another strategy is getting the macrophages, which are negatively influencing the immune system, to turn on the tumor. The tumor puts a protein on the cell surface that signals to the immune system it is a good cell. If that protein is covered, then the immune system will attack it, causing cell death, Ansell explains.


Stephen M. Ansell, MD, PhD, chair of the Lymphoma Group at Mayo Clinic, discusses strategies addressing immune evasion in patients with lymphoma.

One of the most successful strategies to overcome immune evasion is to prevent T cell exhaustion. When T cells get activated and produce proteins such as PD-1, it puts them at risk for being suppressed if the ligand PD-L1 or PD-L2 signals through PD-1, Ansell explains. Other receptors such as TIM-3 and LAG-3 are important, Ansell adds, and those begin to increase as the T cell becomes exhausted. Strategies to keep the immune system engaged involve blocking these negative systems. Blocking PD-1 has already proved to be successful in lymphoma, but there are new trials blocking TIM-3 and LAG-3, Ansell says.

Another strategy is getting the macrophages, which are negatively influencing the immune system, to turn on the tumor. The tumor puts a protein on the cell surface that signals to the immune system it is a good cell. If that protein is covered, then the immune system will attack it, causing cell death, Ansell explains.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x